IPSEN (OTCMKTS:IPSEY) Short Interest Down 39.6% in April

IPSEN (OTCMKTS:IPSEY) was the target of a large decrease in short interest during the month of April. As of April 30th, there was short interest totaling 297 shares, a decrease of 39.6% from the April 15th total of 492 shares. Based on an average trading volume of 680 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.0% of the company’s stock are sold short.

IPSEN Stock Performance

OTCMKTS IPSEY remained flat at $48.76 on Tuesday. The company’s stock had a trading volume of 109 shares, compared to its average volume of 868. IPSEN has a one year low of $28.59 and a one year high of $51.10. The company’s 50-day moving average is $47.28 and its 200-day moving average is $41.70.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research note on Thursday. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold”.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).